<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65312">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01730638</url>
  </required_header>
  <id_info>
    <org_study_id>BRD 11/5-L</org_study_id>
    <nct_id>NCT01730638</nct_id>
  </id_info>
  <brief_title>ImmunoTEP for Patients With Medullary Thyroid Carcinoma.</brief_title>
  <acronym>iTEP-CMT</acronym>
  <official_title>Pharmacokinetic and Imaging Optimization Study of Pretargeted Immuno-PET Using the Anti-CEA x Anti-HSG TF2 Bispecific Antibody and 68Ga-IMP-288 Peptide in Patients With Recurrences of Medullary Thyroid Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Immunomedics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <authority>France : Agence National de Sécurité du Médicament (ANSM)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to optimize pretargeting parameters using pharmacokinetic and
      imaging data for immuno-PET using anti-CEA x anti-HSG TF2 BsMAb and 150 MBq of 68Ga-IMP-288
      peptide in MTC patients with abnormal Ct serum level after initial complete surgery and at
      least one abnormal lesion
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Variation of TF2 molar dose, IMP-288 molar dose and pretargeting interval will be performed
      in 4 to 5 cohorts of 3 patients, receiving 30 to 120 nmol of TF2 and 1.5 to 6 nmol of
      peptides 1 to 3 days apart. Blood samples will be obtained after TF2 and 68Ga-IMP-288
      injections.

      A last cohort (cohorte number 5 or 6) with optimal conditions will be proposed. Whole-body
      PET images will be recorded 60 to 120 minutes after 68Ga-IMP-288 injection to assess
      semi-quantitatively tumor targeting and tumor/background ratio. Moreover, the targeting
      sensitivity of the TF2-pretargeted 68Ga-IMP-288 will be compared to standard methods of
      tumor
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Evaluation of the tumor targeting (No Unit) and signal/noise (No Unit)ratio by immunoTEP with TF2 and 68-Ga-IMP-288</measure>
    <time_frame>one week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Decrease of TF2 and IMP- 288 molar doses and variation of pretargeting interval will be performed in 4 to 5 cohorts of 3 patients, receiving 120 to 30 nmol of TF2 and 6 à 1.5 nmol of peptides 1 to 3 days apart.
A last cohort (number 5 or 6)  with optimal conditions will be proposed Blood samples will be obtained after TF2 and 68Ga-IMP-288 injections. Whole-body PET images will be recorded 60 to 120 minutes after 68Ga-IMP-288 injection to assess semiquantitatively tumor targeting and tumor/background ratio.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensibilité</measure>
    <time_frame>6 monts after immunoTEP</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>tolerance</measure>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Medullary Thyroid Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>• TF2 and 68 Ga-IMP-288</intervention_name>
    <other_name>• TF2: trivalent recombinant humanized antibody recognizing the ACE and the peptide histamine-succinyl-glycine IMP-288 (HSG)</other_name>
    <other_name>• 68 Ga-IMP-288: di-HSG peptide-DOTA-labeled with Gallium 68</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of CMT

          -  Calcitonin&gt; 150 pg / ml

          -  Complete treatment of the primary tumor

          -  at least one detectable lesion more than 10 mm on conventional imaging: bone lesions
             can be taken into account if they extend outside of the bone and the party extra bone
             is measurable.

          -  Age ≥ 18 years

          -  Negative pregnancy test for women of childbearing age in the previous 2 days
             immuno-PET. Women of childbearing potential should use effective contraception take
             continuously for 3 months.

          -  KPS ≥ 70 or ECOG 0-1 and life expectancy of at least 6 months

          -  Absence of serious illness or co-morbidity assessed risk

          -  Creatinine ≤ 2.5 normal

          -  Absence of cancer treatment within 6 weeks prior to the immuno-PET

          -  No history of cancer within 5 years, except skin cancer other than melanoma or
             carcinoma in situ of the cervix

          -  Lack of anti-antibodies in patients who have previously received antibodies and
             hypersensitivity to antibody or protein

          -  Informed consent signed

          -  Social Insurance

        Exclusion Criteria:

          -  Pregnancy or breastfeeding

          -  Serious illness or co-morbidity assessed risk

          -  History of cancer within 5 years, except skin cancer other than melanoma or carcinoma
             in situ of the cervix

          -  Presence of anti-antibodies in patients who have previously received antibodies

          -  Known hypersensitivity to antibody or protein

          -  Need to establish a cancer treatment within 3 months of immuno-PET (before stock
             evaluation 3 months)

          -  Inability intellectual sign consent

          -  Patient protected by law
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francoise Bodere, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Françoise Bodere, PhD, MD</last_name>
    <phone>00320240084136</phone>
    <email>francoise.bodere@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Evelyne Scotet-Cérato, PhD</last_name>
    <phone>0032253482840</phone>
    <email>evelyne.cerato@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Angers Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Couturier, PhD, MD</last_name>
      <email>ocouturier70@me.com</email>
    </contact>
    <investigator>
      <last_name>Olivier Couturier, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Rohmer, PU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>françoise Bodere, PhD, MD</last_name>
      <phone>00320240084136</phone>
      <email>francoise.bodere@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Evelyne Scotet-Cérato, PhD</last_name>
      <phone>0032253482840</phone>
      <email>evelyne.cerato@chu-nantes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Francoise Bodere, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'ouest, René Gauducheau</name>
      <address>
        <city>Sant Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Rousseau, PhD, MD</last_name>
      <phone>0032240679931</phone>
      <email>&quot;evelyne.cerato@chu-nantes.fr&quot; &lt;evelyne.cerato@chu-nantes.fr&gt;</email>
    </contact>
    <contact_backup>
      <last_name>Evelyne Scotet-Cérato, PhD</last_name>
      <phone>0032253482840</phone>
      <email>evelyne.cerato@chu-nantes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Caroline Rousseau, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 22, 2013</lastchanged_date>
  <firstreceived_date>November 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thyroid,</keyword>
  <keyword>endocrine tumour</keyword>
  <keyword>Nuclear medicine,</keyword>
  <keyword>molecular imaging</keyword>
  <keyword>ImmunoTEP</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
